In addition, researchers transfected CHI3L1 siRNA into endometrial cancer cells (HEC-1A), significantly inhibiting CHI3L1 expression and changing HEC-1A migration and invasion potential, suggesting that combining CHI3L1 siRNA with other postoperative chemotherapy may provide more effective treatment for EC patients, effectively preventing postoperative recurrence [154]. Here, CHI3L1 is linked to endometrial cancer.